导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.02% | 1586/4775 |
| 近一周 | -1.05% | 2831/5442 |
| 近一月 | -2.34% | 2632/5404 |
| 近一季 | -1.31% | 2632/5196 |
| 近半年 | -5.59% | 3243/4907 |
| 近一年 | 12.34% | 1353/4336 |
| 近两年 | 70.83% | 1005/2951 |
| 近三年 | 38.68% | 826/2241 |
| 成立以来 | 83.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.71% 1205/4961 |
18.63% 1358/5312 |
- - |
- - |
| 2025 | 30.62% 1304/4813 |
2.16% 1452/3635 |
1.81% 2122/4076 |
24.35% 1479/4524 |
1.00% 1610/4813 |
| 2024 | 6.32% 1772/3463 |
-2.62% 1390/2808 |
-5.23% 1673/3014 |
15.73% 1642/3129 |
-0.46% 1430/3463 |
| 2023 | -6.42% 842/2656 |
7.42% 578/2280 |
-4.18% 1084/2385 |
-4.68% 1201/2515 |
-4.61% 1115/2655 |
| 2022 | -18.03% 652/2207 |
-13.42% 757/1919 |
3.19% 1195/2016 |
-10.46% 408/2113 |
2.48% 923/2208 |
| 2021 | 15.73% 297/1822 |
-1.64% 526/1255 |
9.19% 581/1330 |
4.48% 346/1466 |
3.14% 469/1822 |
| 2020 | 21.32% 692/1250 |
-4.47% 368/1028 |
16.19% 453/1067 |
5.93% 889/1164 |
3.19% 938/1184 |
| 2019 | 25.70% 594/1092 |
30.02% 261/739 |
-9.63% 676/788 |
0.37% 523/850 |
6.59% 584/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.14% 409/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证500ETF联接C VS. 长安沪深300非周期A(740101) |